StockData
Silo Pharma, Inc. logo

Silo Pharma, Inc. (SILO) company profile

SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$1.71+0.14 (+8.57%)

Close on Nov 17, 2026Market cap $2.72MP/E –Yield –

About Silo Pharma

Pharmaceutical Preparations, SIC 2834

Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. In its therapeutics business, the company develops conventional drugs and psychedelic formulations targeting underserved conditions, including post-traumatic stress disorder, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. Its product pipeline features candidates such as SPC-15, an intranasal prophylactic therapy; SP-26, a time-release ketamine implant; SPC-14 for Alzheimer’s disease; and SPU-16 for neuroinflammatory conditions like multiple sclerosis. Its digital asset treasury operations focus on acquiring and staking major cryptocurrencies such as Bitcoin, Ethereum, and Solana to generate yield. The company's customer base consists of patients suffering from psychiatric, chronic pain, and neurological disorders, as well as the broader healthcare and medical community.

The company operates in the United States and maintains intellectual property licensing arrangements with international partners across Europe. It conducts business operations without active commercial sales facilities. Silo Pharma maintains its principal executive offices in Sarasota, Florida.

Summary of the business section of Silo Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Silo Pharma, Inc.
Founded
2010
Headquarters
Sarasota, FL
Address
677 N. Washington Blvd 34236
Phone
(718) 400-9031
Employees
3, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Salberg& Company, P.A., Boca Raton, Florida

Stock & identifiers

Ticker
SILO
Former tickers
PTCI until Sep 30, 2022
Exchange
Nasdaq
Shares outstanding
2M, Aug 13, 2026
Public float
$5.33M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Jun 3, 2026; 1-for-50 reverse, Sep 15, 2022
SEC CIK
1514183
CUSIP
82711P300
ISIN
US82711P3001
FIGI
BBG002D1DZ06
Share class FIGI
BBG002D1DZR7
EIN
46-2137136

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric WeisblumChief Executive Officer, Director214,432
Daniel E. RyweckChief Financial Officer5,000
Wayne LinsleyDirector–
Kevin MunozDirector–
Jeff PavellDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$521.75K$498.54K$101.49K$2–
FY2024$630.05K$630.05K$88.60K$6–
FY2023$569.01K$569.01K$62.69K$7–
FY2022$352.50K$352.50K$15.00K$16–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Eric Weisblum
Chief Executive Officer
$350.00K$83.78K$87.97K$521.75K-17%
Daniel Ryweck
Chief Financial Officer
$60.00K$20.95K$28.55K$101.49K+15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 27, 2026, we employed a total of three full-time employees and we utilize specialized consultants of which we have 3 consultants with yearly contracts and use others from time to time on an as-needed basis.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 29, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 3, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 26, 2022ListingRegistration of securities on an exchange (Form 8-A)
Aug 14, 2020Name changeName changed from Uppercut Brands, Inc. to Silo Pharma, Inc.
May 14, 2019Name changeName changed from Point Capital, Inc. to Uppercut Brands, Inc.
Apr 1, 2019Late filingNotification of late filing
Jan 22, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 20, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 15, 2017Late filingNotification of late filing
Aug 15, 2016Late filingNotification of late filing
Jul 21, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 14, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
May 17, 2016Late filingNotification of late filing
Mar 30, 2016Late filingNotification of late filing
Nov 16, 2015Late filingNotification of late filing
Mar 6, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 7, 2013Name changeName changed from Gold Swap Inc to Point Capital, Inc.

See a number that looks wrong?